BERLIN — – November 13, 2026 -- Germany's budget deliberations have ended without funding for the Standortklausel (location clause), according to industry association Pharma Deutschland. The budget contains only an unbudgeted line item, which the association calls an empty title.
The clause is meant to give the pharmaceutical industry partial relief from additional burdens under the Beitragssatzstabilisierungsgesetz, the association says. Managing Director Dorothee Brakmann says the association was assured in recent days that financing outside statutory health insurance (GKV) had been agreed in principle. No funding has followed. She puts responsibility on the Federal Minister for Economic Affairs, whom the association describes as hesitant, and on the Chancellor.
Pharma Deutschland represents about 400 member companies with about 80,000 employees in Germany, an average of roughly 200 staff per member by our calculation. The association says its members supply almost 80% of over-the-counter medicines sold in pharmacies and almost two-thirds of prescription medicines. Any burden that stays in place therefore reaches a large part of the domestic supply base.
Brakmann says the US and China are actively courting pharmaceutical investment. In her view, each further burden on Germany weakens its position in the competition for the next investment, research project and production line. The association did not disclose the amount it expects the clause to be funded at.
Pharma Deutschland expects the government's pharma strategy, due in a few weeks, to settle the financing question and to set conditions for the German pharma location.